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Background. Patients with chronic hepatitis B virus (HBV) may experience spontaneous biochemical flares of liver disease ac-
tivity. This study aimed to determine (i) the prevalence of prior and possible acute hepatitis E virus (HEV) infection among persons 
with chronic HBV and (ii) whether HEV infection is associated with liver disease flares among persons with chronic HBV.
Methods. Serum from a random sample of 600 adults in the Hepatitis B Research Network Cohort Study was tested for HEV 
RNA and anti-HEV IgM and IgG. Logistic regression models were used to estimate crude and adjusted odds ratios of anti-HEV 
prevalence for participant characteristics.
Results. Anti-HEV IgG and IgM seroprevalence was 28.5% and 1.7%, respectively. No participants had detectable HEV RNA. Of 
the 10 anti-HEV IgM+ participants, only 1 had elevated serum ALT at seroconversion. The odds of anti-HEV seropositivity (IgG+ or 
IgM+) were higher in older participants, males, Asians, less educated people, and those born outside the United States and Canada.
Conclusions. Acute HEV infection is a rare cause of serum ALT flares among persons with chronic HBV. The high seropreva-
lence of anti-HEV IgG among the chronic HBV patients is strongly associated with various demographic factors in this largely Asian 
American cohort.
Keywords. acute hepatitis; HEV; HBV; alanine aminotransferase; flare.
Hepatitis E virus (HEV) is endemic in many developing coun-
tries, where it is transmitted through the fecal–oral route and is 
an important cause of acute hepatitis, fulminant hepatic failure, 
and acute-on-chronic liver disease [1]. In contrast, large-scale 
outbreaks are rare in developed countries due to better infra-
structure, water supply, and sanitation. However, clusters of dis-
ease have been reported in areas of low endemicity that are not 
associated with travel to areas of high endemicity but instead 
are associated with zoonotic transmission [2].
There are at least 5 genotypes of HEV (Orthohepevirus A) 
that infect humans and have different epidemiological features. 
Genotypes 1 and 2 are restricted to humans and are associated 
with fecal–oral transmitted epidemics in developing countries. 
Seroprevalence is estimated to range from 15% to 25% in Africa 
and parts of Asia [3]. In the United States, infection with 
genotypes 1 and 2 is typically found only in persons who have 
recently traveled to countries of high endemicity [4], including 
Mexico and Central America. Genotypes 3 and 4 are associated 
with sporadic cases of acute hepatitis in humans and are com-
monly found in domestic pigs, wild boar, and deer. Genotype 3 is 
found worldwide, whereas genotype 4 is found mainly in eastern 
Asia. Zoonotic transmission of genotypes 3 or 4 can occur 
through consumption of undercooked pig organ meat [5], deer 
meat [6], or contact with infected swine [7, 8]. Additionally, a re-
cent case report described zoonotic transmission of genotype 7 
HEV linked to consumption of camel-derived food products [9].
In Western Europe, genotype 3 HEV infection is increasingly 
recognized as an emerging infection [10], whose transmission 
is thought to be primarily foodborne [11]. HEV can also be 
transmitted by blood transfusion, but this is rare [12]. Although 
typically an acute, self-limiting infection, HEV can establish 
persistent infection among immunosuppressed persons such as 
transplant recipients [13]. Persistent genotype 3 HEV infections 
have been detected in Europe and the United States in trans-
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The extent of autochthonous genotype 3 HEV transmission 
in the United States is unclear, as surveillance efforts have been 
limited, but it may have been underestimated because, in con-
trast to genotypes 1 and 2, viremic persons with no comorbidities 
can be asymptomatic [10, 14, 15]. Furthermore, genotype 3 
HEV infections among persons with underlying chronic liver 
disease may have been missed as clinical features of acute hep-
atitis E are indistinguishable from acute episodes of chronic 
hepatotropic virus infections or drug-induced liver injury [16]. 
In previously asymptomatic persons with chronic hepatitis B 
virus (HBV) infection, we hypothesize that co-infection with 
HEV may be responsible for acute exacerbation of liver disease.
The Hepatitis B Research Network (HBRN) is a National Institutes 
of Health–funded cooperative network that includes 21 clinical sites 
that recruited adult participants into an observational cohort study 
from diverse regions and populations in the United States and 
Canada to better understand the natural history of chronic hepatitis 
B [17]. This ancillary study aimed to examine (i) the seroprevalence 
of anti-HEV among adults with chronic HBV and associated dem-
ographic and clinical features and (ii) whether acute HEV infection 
is associated with the occurrence of serum ALT flares among adults 
with chronic HBV enrolled in the HBRN Adult Cohort Study.
METHODS
Study Design and Sample Selection
Details of the HBRN Cohort Study protocol and characteristics 
of the adult participants have been described previously [17]. 
Institutional review board approval was obtained from all clin-
ical sites. All participants provided written informed consent.
Determining Seroprevalence of Anti-HEV in the HBRN Adult Cohort 
As of November 21, 2016, 1991 HBsAg+ participants were enrolled 
in the HBRN Adult Cohort Study (Figure 1). Of these, 1351 had 
chronic HBV, were not in targeted enrollment groups (eg, acute, 
pregnant, hepatitis D virus [HDV]+, potentially eligible for 1 of the 
clinical trials), and had a serum sample at, or within 48 weeks of, 
study entry. To obtain estimates of the prevalence of HEV viremia 
and anti-HEV seropositivity, a random sample of 600 participants 
was selected and tested for anti-HEV IgG and IgM. Most of the 
participants in the random sample of 600 were noncirrhotic on the 
sample date: 8 participants had cirrhosis before the sample date, 1 
had date of onset of cirrhosis on the sample date, and 1 had date of 
onset of cirrhosis 4 days after the sample date. The next closest cir-
rhosis onset was 15 weeks after the sample date.
Association of Anti-HEV Positivity With Unexplained Liver Disease 
Flares Among Adults With Chronic HBV 
At or after enrollment, there were 122 adjudicated ALT flare 
events, defined as ALT ≥10 times the upper limit of normal 
(ULN; female ≥200 U/L, male ≥300 U/L) among the 1991 
participants (Figure 2). Adjudication included both the date 
the flare began and its etiology. For the aim (ii) analyses, we 
excluded 24 flare events adjudicated as having known eti-
ology (withdrawal of antiviral or immunosuppressive therapy 
[n = 11], HDV coinfection [n = 2], immune tolerant to im-
mune active transition [n = 3], antiviral or drug-induced liver 
injury [n  =  3], pregnancy or miscarriage [n  =  2], and HBV 
related but cannot determine [n  =  3]). The remaining 98 
flare events occurred among 88 individuals. Other exclusions 
were 1 flare that occurred when the participant was receiving 
peginterferon and 15 for whom no serum was available be-
tween 6 weeks before and 12 weeks after the adjudicated flare 
onset date. In the 10 participants who had more than 1 flare 
event after these exclusions, only the first was included. Thus, 
72 flares occurring among 72 participants are included in these 
analyses. Of these 72 flares, 5 flare cases had cirrhosis before 
the sample date (1 of whom was also in the random sample to 
estimate prevalence), 1 had date of onset of cirrhosis 3 weeks 
after the sample date, and the 1 furthest from the sample date 
had date of onset of cirrhosis 7 weeks after the sample date.
To determine whether anti-HEV positivity was associated 
with flare, the 72 cases with at-flare serum were compared with 
288 nonflare controls who were not receiving peginterferon and 
not pregnant from the aim (i) sample. Matching (1 case to 4 
controls) was by propensity of being a flare according to sex, 
age, place of birth, and HBeAg status.
Postflare serum samples >12 weeks and ≤60 weeks after 
adjudicated date of flare onset were available for 51/72 (71%) 
flare cases. Eligible postflare controls were identified by 
nonflare participants who were not receiving peginterferon 
and not pregnant from the aim (i) and also had a subsequent 
serum sample. Similar to at-flare, 51 postflare cases were 1:4 
matched to 204 postflare controls. The propensity score in-
cluded time between samples and sex, age, place of birth, and 
HBeAg status.
HBRN adult cohort





Acute HBV (n = 28)
Targeted enrollees (eg, acute HBV,
pregnant, HDV+, potentially eligible
for 1 of  the clinical trials) (n = 350)
(Database as of  Novemeber 21, 2016)





Figure 1. Sample selection flowchart for aim (1) seroprevalence of anti-HEV in 
the HBRN Adult Cohort. Abbreviations: HBRN, Hepatitis B Research Network; HBV, 
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Finally, to test whether anti-HEV positivity differed over 
time, preflare was compared with at-flare (n = 49) and postflare 
(n = 35), and at-flare was compared with postflare (n = 51). No 
participants decompensated in the time between preflare and 
postflare sample for this study.
Enzyme-Linked Immunosorbent Assays for Anti-HEV IgM and IgG
Serum samples were tested for anti-HEV IgM and IgG by 
enzyme-linked immunosorbent assay (ELISA). Commercial 
ELISA kits for the detection of anti-HEV IgM and IgG in human 
sera were purchased from Wantai (Beijing, China). Each sample 
was tested in duplicate. Assays were performed according to the 
manufacturer’s instructions, and absorbance at 450  nm was 
measured using a Synergy Neo2 plate reader (Biotek, Winooski, 
VT). For those samples that tested positive for anti-HEV IgM, 
longitudinal analyses were performed to authenticate the initial 
test result.
RNA Extraction and Quantitative Reverse Transcription Polymerase Chain 
Reaction Detection of HEV RNA
RNA was extracted from 200-µL serum samples using the 
ZR-96 Viral RNA Kit (Zymo Research, Irvine, CA). Purified 
RNA was eluted into 15  µL of RNase-free molecular-
grade water. HEV RNA was measured using a previously 
validated Taqman reverse transcription polymerase chain 
reaction (RT-PCR) assay with primers and probe targeting 
a region in the viral ORF3 region that is highly conserved 
between genotypes [18, 19]. RNA was quantified by com-
parison with a standard curve based on serial dilutions of 
genotype 3 HEV Kernow C1 (p6) genomic RNA that were 
generated by in vitro transcription from a cDNA clone [20]. 
The standard curve was compared with the World Health 
Organization international standard for HEV RNA (code 
number 6329/10) [21] to calculate a limit of detection for 
the assay of 75 IU.
HBRN adult cohort
110 participants/122 flare events
at or after enrollment (ALT ≥ 10xULN:
female ≥ 200, male ≥ 300U/L)
Excluded 24 flare events
Withdrawal of  antiviral or immunosuppressive therapy (n = 11)
HDV coinfection (n = 2)
Immune tolerant to immune active transition (n = 3)
Antiviral or drug induced (n = 3)
Pregnancy or miscarriage (n = 2)
HBV related but cannot determine (n = 3)
Excluded 1 flare under peginterferon
Excluded 15 flares without serum between –6 weeks to +12 weeks
Excluded 10 flares within same individuals
72 flare etiologies: spontaneous viral reactivation (n = 32, 44.4%)
unsuccessful or spontaneous immune clearance (n = 21, 29.2%), no






(–6 to 12 weeks)




(1 to 4 matching) (1 to 4 matching)
Postflare sample
n = 51
(>12 to 60 weeks)
Cases
Controls
88 participants/98 flare events
72 participants were selected as flare cases
Figure 2. Sample selection flowchart for aim (2): association between HEV infection and liver disease flares among persons with chronic HBV. aAt-flare samples: cases 
and controls were matched by propensity scores accounting for sex, age, place of birth, and HBeAg status. bPostflare samples: cases and controls were matched by propen-
sity scores accounting for sex, age, place of birth, HBeAg status, and time between samples. a,bExclusion criteria for both cases and controls: samples from participants on 
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Statistical Analyses
Determining Seroprevalence of Anti-HEV and Associations With 
Clinical and Demographic Characteristics
Seroprevalence (%) was calculated by the number of the 600 
participants with each type of infection divided by the number 
tested, multiplied by 100. Ninety-five percent exact confi-
dence intervals about the prevalence estimates were calculated. 
Demographic and clinical characteristics were summarized 
by HEV infection status. Categorical data were summarized 
with frequencies and percentages, and continuous data were 
summarized as mean (standard deviation) or median (25th 
and 75th percentiles), depending on the distribution. The 
Kruskal-Wallis test or Pearson’s chi-square test was used to 
test whether distributions of continuous or categorical char-
acteristics, respectively, differed between anti-HEV+ and 
anti-HEV- participants. Characteristics included age, sex, race 
(Asian, non-Asian), time since migration (ie, US/Canada born, 
migrated >20 years ago, migrated ≤20 years ago), geographical 
region of enrollment, education level, employment status, ALT, 
log10 HBV DNA, genotype, and HBeAg. Simple logistic regres-
sion models were used to test for differences in the seropreva-
lence of HEV by participant characteristics.
Multiple logistic regression models were fit stepwise and used 
to examine the independent (adjusted) associations between se-
roprevalence and demographic and clinical characteristics. The 
criterion for both entry and removal from the models was a P 
value ≤0.05. The results are presented as odds ratios (ORs), 95% 
confidence intervals (CIs), and P values.
Association of Anti-HEV Positivity With Liver Disease Flares Among 
Persons With Chronic HBV
The odds of having an ALT flare were compared between 
participants who were anti-HEV positive and those who were 
anti-HEV negative using conditional logistic regression to ac-
count for the propensity score matching of nonflare controls 
to flare cases, both at time of flare and postflare. To determine 
whether flares were associated with seroconversion from anti-
HEV negative to positive, McNemar’s test was used to test 
whether seroprevalence of anti-HEV changed pre- vs at-, pre- 
vs post-, and at- vs postflare.
SAS 9.4 and R 3.4.2 were used for statistical analysis and 
graphical displays.
RESULTS
Prevalence of HEV Infection in the HBRN Adult Cohort
Among the 600 randomly selected study participants from 
the HBRN adult cohort, the median age was 42  years, 50.7% 
were female, 72.5% were Asian, and 19.4% were US or Canada 
born (Table 1). Seroprevalence of anti-HEV+, defined as ei-
ther anti-HEV IgM positive or anti-HEV IgG positive, was 
29%. There were significant differences in anti-HEV preva-
lence by age (higher prevalence in older participants), males 
(34.8%) vs females (23.4%), Asians (31.8%) vs non-Asians 
(21.2%), immigrants (32.1%) vs those born in the United States 
or Canada (16.0%), and those with less than a Bachelor’s de-
gree (35.3%) vs at least a Bachelor’s degree (20.6%). Active vi-
remia (detectable HEV RNA) was not detected in any of the 600 
samples. Regarding serological evidence of remote and recent 
acute infection (Table 2), 71.0% were anti-HEV IgG and IgM 
negative, 27.3% (n  =  164) were anti-HEV IgG (+) only, 0.5% 
(n = 3) were IgM (+) only, and 1.2% (n = 7) were both IgG (+) 
and IgM (+). Therefore, the seroprevalence of anti-HEV IgG 
and IgM was 28.5% (95% CI, 24.9%–32.3%) and 1.7% (95% 
CI, 0.8%–3.0%), respectively. Median ALT for the 10 anti-HEV 
IgM+ participants (range) was 27.5 (9–76) U/L.
HEV seroprevalence was examined by geographical region 
based upon site of enrollment (Supplementary Table 1). HEV 
seroprevalence among participants from the Canadian site 
was the highest (42%), followed by sites in the US-West (37%), 
US-Midwest (26%), US-Southwest (23%), US-Southeast (19%), 
and US-Northeast (18%). Geographical region was strongly as-
sociated with the 2 categories of race (Asian vs non-Asian: chi-
square test P  <  .0001): 89% of the participants at the sites in 
the US-West were Asian, and 85% were Asian at the Canadian 
site, compared with 56% at sites in the US-Southeast and 58% at 
sites in the US-Midwest. Thus, in the multivariable model, race 
(Asian/non-Asian) was used, not region.
In the multivariable (adjusted) logistic regression model, 
characteristics significantly and independently (P  <  .05) as-
sociated with higher seroprevalence of HEV were older age, 
male, Asian race, less education, and positive HBeAg (Table 3). 
Although those who migrated to the United States or Canada 
more than 20 years ago did not have a significantly different se-
roprevalence of HEV than those born in the United States or 
Canada, more recent immigrants had significantly higher se-
roprevalence than those born in the United States or Canada.
The association of education with HEV seroprevalence varies 
by race (P value for race × education interaction  =  0.046). 
Among participants with less than a Bachelor’s degree, Asians 
had 2.9 times higher odds of HEV seroprevalence than non-
Asians, whereas the odds of HEV seroprevalence were similar 
between Asians and non-Asians among those who had at least a 
Bachelor’s degree (Table 3).
Longitudinal Analyses of Sera From Anti-HEV IgM-Positive Subjects
To further authenticate the 10 anti-HEV IgM-positive subjects, 
archival sera from before and after the initial positive re-
sult were assayed for anti-IgM and IgG (Figure 3). Only 4/10 
subjects (Figure 3A–D) were confirmed as recent infections 
based on anti-HEV IgM and IgG kinetic characteristics of the 
convalescence phase of acute HEV (anti-HEV IgM positive but 
declining, anti-HEV IgG increasing). Of these 4 subjects, only 1 
(Figure 3 D) had increased ALT around the time of seroconver-
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Table 1. Participants’ Characteristics by Anti-HEV Positivity
Characteristics
Total Anti-HEV (-) Anti-HEV (+)
P Valuean = 600 n = 426 (71%) n = 174 (29%)
Age at current study visit, y n = 600 n = 426 n = 174 <.001
 Median (25th %-ile: 75th %-ile) 42.1 (32.8: 53.0) 39.8 (31.4: 50.6) 47.7 (38.1: 58.1)  
Age stratum, No. (%) n = 600 n = 426 n = 174 <.001
 18–<30 y 103 (17.2) 83 (80.6) 20 (19.4)  
 30–<40 y 163 (27.2) 135 (82.8) 28 (17.2)  
 40–<50 y 143 (23.8) 97 (67.8) 46 (32.2)  
 50+ y 191 (31.8) 111 (58.1) 80 (41.9)  
Sex, No. (%) n = 600 n = 426 n = 174 .002
 Female 304 (50.7) 233 (76.6) 71 (23.4)  
 Male 296 (49.3) 193 (65.2) 103 (34.8)  
Race, No. (%) n = 599 n = 426 n = 173 .01
 Non-Asian 165 (27.5) 130 (78.8) 35 (21.2)  
 Asian 434 (72.5) 296 (68.2) 138 (31.8)  
Time since migration, No. (%) n = 545 n = 387 n = 158 .001b
 Born in US/Canada 106 (19.4) 89 (84.0) 17 (16.0)  
 Born outside US/Canada 439 (80.6) 298 (67.9) 141 (32.1) .83c
  Migrated >20 y ago 187 (42.6) 128 (68.4) 59 (31.6)  
  Migrated ≤20 y ago 252 (57.4) 170 (67.5) 82 (32.5)  
Education level, No. (%) n = 594 n = 426 n = 168 <.001
 Bachelor’s or higher 282 (47.5) 224 (79.4) 58 (20.6)  
 Less than Bachelor’s 312 (52.5) 202 (64.7) 110 (35.3)  
Employment status, No. (%) n = 597 n = 426 n = 171 .28
 Employed, full-time or part-time 447 (74.9) 326 (72.9) 121 (27.1)  
 Homemaker, not currently working for pay 25 (4.2) 18 (72.0) 7 (28.0)  
 Not currently employed 125 (20.9) 82 (65.6) 43 (34.4)  
ALT, U/L n = 595 n = 425 n = 170 .41
 Median (25th %-tile: 75th %-tile) 33 (22: 51) 31 (22: 51) 35 (22: 52)  
HBV DNA, log10 IU/mL n = 600 n = 426 n = 174 .23
 Median (25th %-ile: 75th %-ile) 3.5 (2.3: 5.3) 3.5 (2.3: 5.1) 3.7 (2.6: 5.6)  
Genotype, No. (%) n = 555 n = 391 n = 164 .79
 A 90 (16.2) 65 (72.2) 25 (27.8)  
 B 224 (40.4) 154 (68.8) 70 (31.3)  
 C 176 (31.7) 123 (69.9) 53 (30.1)  
 D 44 (7.9) 32 (72.7) 12 (27.3)  
 Other: E, F, or multiple genotypes 21 (3.8) 17 (81.0) 4 (19.0)  
HBeAg, No. (%) n = 600 n = 426 n = 174 .92
 Negative 464 (77.3) 329 (70.9) 135 (29.1)  
 Positive 136 (22.7) 97 (71.3) 39 (28.7)  
Abbreviations: HBV, hepatitis B virus; HEV, hepatitis E virus.
aP values were obtained using the Kruskal Wallis test for continuous variables and Pearson’s chi-square test for categorical variables.
bP value was obtained using a Pearson’s chi-square test between those born in the US/Canada and born outside the US/Canada.
cP value was obtained using a Pearson’s chi-square test between those who migrated >20 years ago and those who migrated ≤20 years ago.
Table 2. Anti-HEV IgG and Anti-HEV IgM Distributions Among 600 Participants
Anti-HEV Status HEV Infection Status Anti-HEV IgM Status Anti-HEV IgG Status No. % (95% CIa)
Negative No infection Negative Negative 426 71.0 (67.2–74.6)
Positive Remote Negative Positive 164 27.3 (23.8–31.1)
Recent Positive Negative 3 0.5 (0.1–1.5)
  Positive Positive 7 1.2 (0.5–2.4)
Abbreviations: CI, confidence interval; HEV, hepatitis E virus.
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Subjects E–H were anti-HEV IgM positive at week 0 with IgM 
declining over time but no increase in anti-HEV IgG. Subjects 
E–H may have been exposed to HEV but failed to develop long-
lived IgG responses. Alternatively, the initial anti-HEV IgM may 
have been a false positive. Subjects I and J only had sera avail-
able from 1 additional time point; thus the longitudinal analyses 
are difficult to interpret. Subject I was initially anti-HEV IgG 
positive and IgM negative and 28 weeks later remained positive 
for IgG (albeit at lower levels) but became anti-HEV IgM pos-
itive, possibly indicating re-infection. Subject J was anti-HEV 
IgM positive and IgG negative at week 0. The only additional 
sample for subject J was from 184 weeks later, which also tested 
positive for anti-HEV IgM but was negative for IgG. This case 
could either represent anti-HEV IgM false positives or mild, 
acute infections that were not accompanied by development of 
HEV-specific IgG.
In summary, using highly stringent criteria for recent infec-
tion based on longitudinal analyses (anti-HEV IgM positive but 
declining with anti-HEV IgG increasing over time), the prev-
alence of recent HEV infection was 0.7% (4/600 samples; 95% 
CI, 0.2%–1.7%).
Testing Whether Anti-HEV Positivity Is Associated With Liver Disease 
Flares Among Persons With Chronic HBV
The etiologies of the 72 flare cases included spontaneous viral 
reactivation (n = 32, 44.4%), unsuccessful or spontaneous im-
mune clearance (n  =  21, 29.2%), no changes in HBV DNA 
(n = 11, 15.3%), and other or unknown (n = 8, 11.1%) (Figure 
2). The seroprevalence of anti-HEV (IgM+ and/or IgG+) 
was similar among at-flare samples in cases (36%; median 
ALT,  365 U/L) and matched controls (35%; median ALT,  29 
U/L) (Supplementary Figure 1A). The seroprevalence rates of 
anti-HEV were also similar among flare cases’ postflare samples 
(31%; median ALT, 68 U/L) compared with matched postflare 
controls (29%; median ALT,  32 U/L) (Supplementary Figure 
1B). The odds of flaring were not significantly different between 
anti-HEV positive (IgG+ or IgM+) and anti-HEV negative 
(IgG- and IgM-) participants (OR, 1.3; 95% CI, 0.7–2.5) for the 
at-flare and matched samples (Supplementary Table 2). Similar 
results were found using postflare matched samples (OR, 1.2; 
95% CI, 0.6–2.6).
Among 72 flare cases, seroprevalence of anti-HEV was sim-
ilar pre- (29%), at- (36%), and postflare (31%) (Supplementary 
Figure 1C), and seroprevalence of anti-HEV did not differ sig-
nificantly between pre- vs at- (P = .45), pre- vs post- (P = .51), 
and at- vs postflare (P = .55) (Supplementary Table 3).
DISCUSSION
This study showed that acute HEV infection is a rare cause 
of spontaneous flares in persons with chronic hepatitis B 
in the United States and Canada. Initial screening of 600 
serum samples randomly selected from eligible HBRN adult 
participants identified 10 subjects who were positive for anti-
HEV IgM. Previous studies have noted variation in the perfor-
mance of commercial assays for the detection of HEV-specific 
IgM [22]. There is no confirmatory assay for anti-HEV IgM 
antibodies, but false-positive rates are very low [22]. To fur-
ther authenticate the 10 IgM-positive results, longitudinal 
analyses were performed to determine whether these anti-HEV 
IgM-positive measurements were biologically plausible. Of the 
10 subjects, only 4 showed anti-HEV IgM declining and IgG 
increasing over time, providing a more stringent estimate of 
HEV IgM seroprevalence at 4/600 or 0.7%. This leaves 6 out 
of the 10 cases that were originally identified as anti-HEV IgM 
positive as unconfirmed. However, this may be overly strin-
gent, as recent studies suggest that immunocompetent people 
infected with HEV in industrialized countries do not always 
develop a persistent humoral response to the virus and a sus-
tained specific IgG response may be associated with repeated 
exposures [23]. Of the 10 anti-HEV IgM-positive subjects, 
only 1 showed elevated ALT just before seroconversion. This 
flare was transient and without jaundice. ALT elevation may 
have been missed in the other IgM-positive subjects if it was 
transient and normalized by the time of the subject’s clinic 
visit. Asymptomatic infection with genotype 3 HEV is not un-
common, and studies of blood donors have detected HEV in-
fection in the context of normal ALT levels [24].
For 2 of the anti-HEV IgM-positive subjects, there was ev-
idence for remote infection followed by reinfection. There 
is evidence in the literature of sero-reversion and reinfection 







Age at current study visit, y P < .001
 Per-year increase 1.05 (1.03–1.07)
Sex P < .001
 Female 1.00 (reference)
 Male 2.10 (1.39–3.19)
Race and education level P = .046
 Bachelor’s or higher: Asian vs non-Asian 1.08 (0.50–2.33)
 Less than Bachelor’s: Asian vs non-Asian 2.92 (1.42–6.01)
Time since migration P = .045
 Born in US/Canada 1.00 (reference)
 Migrated >20 y 1.30 (0.62–2.74)
 Migrated ≤20 y 2.09 (1.03–4.25)
HBeAg P = .036
 Negative 1.00 (reference)
 Positive 1.74 (1.04–2.93)
Abbreviations: CI, confidence interval; HEV, hepatitis E virus.
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from longitudinal studies of immunocompetent patients with 
hemoglobinopathies who received multiple transfusions [23].
The seroprevalence of 28.5% (95% CI, 24.9%–32.3%) for anti-
HEV IgG among persons with chronic HBV is higher compared 
with the general population in the United States, where sero-
prevalence was 21.0% (95% CI, 19.0%–22.9%) based on testing 
of participants in the Third National Health and Nutrition 
Examination Survey (NHANES III) from 1988 to 1994 [25]. 
More recently, anti-HEV IgG seroprevalence was found to be 
6.0% (95% CI, 5.1%–6.9%) based on data from the NHANES 
2009–2010 survey [26]. Differences in assay sensitivity between 
the 2 studies may partly account for the decline in HEV IgG 
seroprevalence, but analyses of samples from the different time 
periods using the same assay showed that anti-HEV prevalence 
was decreasing in the United States [27]. However, neither of 
the studies of NHANES participants used the Wantai commer-
cial assay that was used in this study. Of commercial assays, sev-
eral studies have found the Wantai anti-HEV IgG assay to have 
high sensitivity (>99%) and specificity (>96%) [28–33]. A study 
that tested US blood donors for anti-HEV IgG using the Wantai 
ELISA found a seroprevalence of 18.8% (95% CI 17.0%–20.5%) 
in samples donated in 2006 and 2012 [34]. Compared with US 
blood donors, anti-HEV IgG prevalence among persons with 
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Figure 3. Follow-up longitudinal analysis of antibody responses to HEV among 10 subjects who tested positive for anti-HEV IgM out of a random sample of 600 subjects 
from the adult HBRN cohort. To authenticate anti-HEV IgM positive samples, further samples were tested from the same subjects, both before and after the initial IgM posi-
tive result. For each subject, antibody responses to HEV are expressed as signal/cut-off (S/CO) and plotted against time (weeks) where the initial anti HEV IgM positive test is 
shown as week 0. Anti-HEV IgM is plotted on the left y-axis (red open circles) and IgG is plotted on the far-left y-axis (green open squares). Serum ALT is plotted on the right 
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higher (28.5%; 95% CI, 24.9%–32.3%; P < .001). This difference 
could be due to HEV exposure in endemic regions of the world, 
because in our sampling of adult HBRN participants, 80.6% were 
born outside the United States or Canada. We found higher se-
roprevalence among persons born outside the United States and 
Canada, likely reflecting acquisition of acute HEV infection in 
areas of high endemicity and virus clearance before immigration. 
Additionally, higher seroprevalence was associated with lower 
education levels (less than a Bachelor’s degree) among persons 
of Asian race. This may reflect higher risk of remote exposure 
to HEV (ie, before migration) among persons of lower socioeco-
nomic status who immigrated from endemic regions.
HEV RNA was not detected in any of the participants, con-
sistent with the short duration of viremia during acute HEV in-
fection and previous reports of low prevalence of HEV viremia 
in the United States—1:42 000 or 1:9500 based on screens of 
blood donors [35] or plasma donors [36], respectively. HEV 
RNA was not measured in liver tissue or stool, neither of which 
was collected as part of the current observational study.
We did not find an association between ALT flares and previ-
ously undiagnosed HEV infection (as determined by serocon-
version to anti-HEV IgG positive after the flare) among 72 flare 
cases. The lack of association between ALT flares and HEV in-
fection in this study may be due to the small sample sizes that 
were available longitudinally among flare cases (Supplementary 
Table 2) or the low prevalence of acute HEV infection in our 
study sample (ie, only 1 subject who experienced an ALT flare 
tested IgM+). A recent study showed that among patients with 
acute HEV infection at public hospitals and clinics in Hong 
Kong, those with underlying chronic hepatitis B had signifi-
cantly worse disease outcomes and higher mortality [37].
As discussed above, the seroprevalence of HEV-specific IgG 
was higher among persons of Asian race and persons born out-
side the United States or Canada. No information is available 
concerning whether these participants immigrated from re-
gions of high HEV prevalence. It is interesting to speculate that 
they may have been exposed to acute (genotype 1 or 2) HEV 
infection and developed protective immunity before migration 
and thus be less likely to develop HEV infection following sub-
sequent exposure to genotype 3 HEV in North America.
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line. Consisting of data provided by the authors to benefit the reader, the posted 
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